AN ACT RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION REVIEW ACT

SB 2109 prohibits health insurers and pharmacy benefit managers from requiring or conducting insurance reviews for prescriptions used to treat opioid or alcohol use disorder. Specifically, it blocks reviews for medications containing methadone, buprenorphine, or naltrexone, or for any FDA-approved medication managing opioid withdrawal. The bill directly affects patients seeking addiction treatment and insurers/pharmacy managers handling these prescriptions. It also requires Medicaid managed care organizations to use state-set medical necessity criteria for reviews. The law takes effect upon passage.